New Drug for Mantle Cell Lymphoma

A new combination treatment eliminating many of the side effects of traditional chemotherapy for mantle cell lymphoma has shown favorable response in a two-year trial according to Weill Cornell Medicine research.  The pill Lenalidomide, taken in combination with the antibody Rituximab shrunk tumor size by more than more than half in 90% of the patients enrolled in a small efficacy clinical trial.  And, more than two-thirds of the group had no evidence of a detectable tumor after treatment completed.  Long-term outcomes found that patients were able to resume their daily lifestyle with a higher quality of life while undergoing treatment.  You can read more about this exciting research and the findings published in the New England Journal of Medicine by clicking here.

 

Tags: , , , , , , , ,

Leave a Comment